Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62.
Article
CAS
PubMed
PubMed Central
Google Scholar
Peeri NC, Shrestha N, Rahman MS, Zaki R, Tan Z, Bibi S, et al. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? Int J Epidemiol. 2020;49(3):717–26.
Article
PubMed
Google Scholar
Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. Extrapulmonary manifestations of COVID-19. Nat Med. 2020;26(7):1017–32.
Article
CAS
PubMed
Google Scholar
Zheng KI, Feng G, Liu WY, Targher G, Byrne CD, Zheng MH. Extrapulmonary complications of COVID-19: a multisystem disease? J Med Virol. 2020;93:323–35.
Article
PubMed
CAS
Google Scholar
Yang W, Sirajuddin A, Zhang X, Liu G, Teng Z, Zhao S, et al. The role of imaging in 2019 novel coronavirus pneumonia (COVID-19). Eur Radiol. 2020;30:4874–82.
Article
CAS
PubMed
PubMed Central
Google Scholar
Vabret N, Britton GJ, Gruber C, Hegde S, Kim J, Kuksin M, et al. Immunology of COVID-19: current state of the science. Immunity. 2020;52(6):910–41.
Article
CAS
PubMed
PubMed Central
Google Scholar
McGonagle D, Sharif K, O’Regan A, Bridgewood C. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev. 2020;19(6):102537.
Article
CAS
PubMed
PubMed Central
Google Scholar
McGonagle D, O’Donnell JS, Sharif K, Emery P, Bridgewood C. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol. 2020;2:e437–45.
Article
PubMed
PubMed Central
Google Scholar
Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335–7.
Article
CAS
PubMed
PubMed Central
Google Scholar
Al-Quteimat OM, Amer AM. The impact of the COVID-19 pandemic on cancer patients. Am J Clin Oncol. 2020;43(6):452–5.
Article
CAS
PubMed
Google Scholar
Johnson KM, Belfer JJ, Peterson GR, Boelkins MR, Dumkow LE. Managing COVID-19 in renal transplant recipients: a review of recent literature and case supporting corticosteroid-sparing immunosuppression. Pharmacotherapy. 2020;40(6):517–24.
Article
CAS
PubMed
Google Scholar
Favalli EG, Agape E, Caporali R. Incidence and clinical course of COVID-19 in patients with connective tissue diseases: a descriptive observational analysis. J Rheumatol. 2020;47(8):1296.
Article
CAS
PubMed
Google Scholar
Mathian A, Mahevas M, Rohmer J, Roumier M, Cohen-Aubart F, Amador-Borrero B, et al. Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine. Ann Rheum Dis. 2020;79(6):837–9.
Article
CAS
PubMed
Google Scholar
Ouedraogo DD, Tiendrebeogo WJS, Kabore F, Ntsiba H. COVID-19, chronic inflammatory rheumatic disease and anti-rheumatic treatments. Clin Rheumatol. 2020;39(7):2069–75.
Article
PubMed
PubMed Central
Google Scholar
Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020. https://doi.org/10.1001/jama.2020.6019.
Article
PubMed
PubMed Central
Google Scholar
Dos Reis Neto ET, Kakehasi AM, de Medeiros PM, Ferreira GA, Marques CDL, da Mota LMH, et al. Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases. Adv Rheumatol. 2020;60(1):32.
Article
PubMed
PubMed Central
Google Scholar
Fanouriakis A, Bertsias G, Boumpas DT. Hydroxychloroquine dosing in systemic lupus erythematosus: response to ‘Comment on the 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus by Fanouriakis et al’ by Costedoat-Chalumeau et al. Ann Rheum Dis. 2020;79(8):e91.
Article
PubMed
Google Scholar
Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I, et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020;79(6):713–23.
Article
CAS
PubMed
Google Scholar
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–71.
Article
CAS
PubMed
PubMed Central
Google Scholar
Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1):105949.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lagier JC, Million M, Gautret P, Colson P, Cortaredona S, Giraud-Gatineau A, et al. Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: a retrospective analysis. Travel Med Infect Dis. 2020;36:101791.
Article
PubMed
PubMed Central
Google Scholar
Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M, et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Netw Open. 2020;3(4):e208857.
Article
PubMed
Google Scholar
Monteiro WM, Brito-Sousa JD, Baia-da-Silva D, Melo GC, Siqueira AM, Val F, et al. Driving forces for COVID-19 clinical trials using chloroquine: the need to choose the right research questions and outcomes. Rev Soc Bras Med Trop. 2020;53:e20200155.
Article
PubMed
PubMed Central
Google Scholar
Cortegiani A, Ippolito M, Ingoglia G, Iozzo P, Giarratano A, Einav S. Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19. J Crit Care. 2020;59:176–90.
Article
CAS
PubMed
PubMed Central
Google Scholar
Cortegiani A, Ippolito M, Ingoglia G, Einav S. Chloroquine for COVID-19: rationale, facts, hopes. Crit Care. 2020;24(1):210.
Article
PubMed
PubMed Central
Google Scholar
Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020;57:279–83.
Article
CAS
PubMed
PubMed Central
Google Scholar
Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A, et al. Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. N Engl J Med. 2020;383:2041–52.
Article
CAS
PubMed
Google Scholar
Gentry CA, Humphrey MB, Thind SK, Hendrickson SC, Kurdgelashvili G, Williams RJ 2nd. Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study. Lancet Rheumatol. 2020;2(11):e689–97.
Article
PubMed
PubMed Central
Google Scholar
Aringer M, Costenbader K, Dorner T, Johnson SR. SLE classification criteria items are not dependent on current activity but may accumulate over time. Response to: 'Do 2019 European League against rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus also indicate the disease activity?' by Teng et al. Ann Rheum Dis. 2020.
https://doi.org/10.1136/annrheumdis-2020-217105.
Article
PubMed
Google Scholar
Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69(9):1580–8.
Article
PubMed
Google Scholar
Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjogren’s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis. 2017;76(1):9–16.
Article
PubMed
Google Scholar
van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65(11):2737–47.
Article
PubMed
PubMed Central
Google Scholar
Lundberg IE, Tjarnlund A, Bottai M, Werth VP, Pilkington C, de Visser M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Arthritis Rheumatol. 2017;69(12):2271–82.
Article
PubMed
PubMed Central
Google Scholar
Sharp GC, Irvin WS, Tan EM, Gould RG, Holman HR. Mixed connective tissue disease–an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med. 1972;52(2):148–59.
Article
CAS
PubMed
Google Scholar
Altman R, Alarcon G, Appelrouth D, Bloch D, Borenstein D, Brandt K, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis Rheum. 1990;33(11):1601–10.
Article
CAS
PubMed
Google Scholar
Altman RD, Block DA, Brandt KD, Cooke DV, Greenwald RA, Hochberg MC, et al. Osteoarthritis: definitions and criteria. Ann Rheum Dis. 1990;49(3):201.
Article
CAS
PubMed
PubMed Central
Google Scholar
Javelle E, Gautret P, Simon F. Chikungunya, the emerging migratory rheumatism. Lancet Infect Dis. 2015;15(5):509–10.
Article
PubMed
Google Scholar
MdSB. Boletim Epidemiológico—Doença pelo Coronavírus 2019. Ampliação da Vigilância, Medidas não Farmacológicas e Descentralização do Diagnóstico Laboratorial. In: Saúde Md, editor Brasil 2020. 2020.
Zen M, Fuzzi E, Astorri D, Saccon F, Padoan R, Ienna L, et al. SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: a cross-sectional study on 916 patients. J Autoimmun. 2020;112:102502.
Article
CAS
PubMed
PubMed Central
Google Scholar
Figueroa-Parra G, Aguirre-Garcia GM, Gamboa-Alonso CM, Camacho-Ortiz A, Galarza-Delgado DA. Are my patients with rheumatic diseases at higher risk of COVID-19? Ann Rheum Dis. 2020;79(6):839–40.
Article
CAS
PubMed
Google Scholar
Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79(7):859–66.
Article
CAS
PubMed
Google Scholar
D’Silva KM, Serling-Boyd N, Wallwork R, Hsu T, Fu X, Gravallese EM, et al. Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US “hot spot.” Ann Rheum Dis. 2020;80:e64.
Article
PubMed
Google Scholar
Marques C, Pinheiro MM, Reis Neto ET, Dantas AT, Ribeiro FM, Melo AKG. COVID-19 in patients with rheumatic diseases: what is the real mortality risk? Ann Rheum Dis. 2020. https://doi.org/10.1136/annrheumdis-2020-218431.
Article
PubMed
Google Scholar
Schrezenmeier E, Dorner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16(3):155–66.
Article
CAS
PubMed
Google Scholar
The L. COVID-19: learning from experience. Lancet. 2020;395(10229):1011.
Article
Google Scholar
Fineberg HV. Ten weeks to crush the curve. N Engl J Med. 2020;382(17):e37.
Article
CAS
PubMed
Google Scholar
Wei WE, Li Z, Chiew CJ, Yong SE, Toh MP, Lee VJ. Presymptomatic transmission of SARS-CoV-2 - Singapore, January 23–March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(14):411–5.
Article
CAS
PubMed
PubMed Central
Google Scholar
Klompas M, Morris CA, Shenoy ES. Universal masking in the Covid-19 era. N Engl J Med. 2020;383(2):e9.
Article
CAS
PubMed
Google Scholar
Klompas M, Morris CA, Sinclair J, Pearson M, Shenoy ES. Universal masking in hospitals in the Covid-19 Era. N Engl J Med. 2020;382(21):e63.
Article
CAS
PubMed
Google Scholar
Wilder-Smith A, Freedman DO. Isolation, quarantine, social distancing and community containment: pivotal role for old-style public health measures in the novel coronavirus (2019-nCoV) outbreak. J Travel Med. 2020;27(2):taaa020. https://doi.org/10.1093/jtm/taaa020.
Article
PubMed
Google Scholar
Paton NI, Lee L, Xu Y, Ooi EE, Cheung YB, Archuleta S, et al. Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial. Lancet Infect Dis. 2011;11(9):677–83.
Article
CAS
PubMed
Google Scholar
Paton NI, Goodall RL, Dunn DT, Franzen S, Collaco-Moraes Y, Gazzard BG, et al. Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial. JAMA. 2012;308(4):353–61.
Article
CAS
PubMed
Google Scholar
Konig MF, Kim AH, Scheetz MH, Graef ER, Liew JW, Simard J, et al. Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19. Ann Rheum Dis. 2020;79:1386–8.
Article
CAS
PubMed
Google Scholar
Carmichael SJ, Charles B, Tett SE. Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis. Ther Drug Monit. 2003;25(6):671–81.
Article
CAS
PubMed
Google Scholar
Morita S, Takahashi T, Yoshida Y, Yokota N. Population pharmacokinetics of hydroxychloroquine in Japanese patients with cutaneous or systemic lupus erythematosus. Ther Drug Monit. 2016;38(2):259–67.
Article
CAS
PubMed
Google Scholar
Cui C, Tu S, En VSJ, Li X, Yao X, Li H, et al. Review on the clinical pharmacology of hydroxychloroquine sulfate for the treatment of COVID-19. Curr Drug Metab. 2020;21:427–35.
Article
CAS
PubMed
Google Scholar
Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020;71(15):732–9.
Article
CAS
PubMed
Google Scholar
Calisher C, Carroll D, Colwell R, Corley RB, Daszak P, Drosten C, et al. Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19. Lancet. 2020;395(10226):e42–3.
Article
CAS
PubMed
PubMed Central
Google Scholar
Gao J, Hu S. Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19). Biosci Trends. 2020;14(2):156–8.
Article
CAS
PubMed
Google Scholar
Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72–3.
Article
CAS
PubMed
Google Scholar
Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis. 2020;79(5):667–8.
Article
CAS
PubMed
Google Scholar
Lahouati M, Meriglier E, Martin L, Bouchet S, Desclaux A, Bonnet F. COVID-19 infection also occurs in patients taking hydroxychloroquine. J Antimicrob Chemother. 2020;75(7):2014–5.
Article
CAS
PubMed
Google Scholar
Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020;395(10223):470–3.
Article
CAS
PubMed
PubMed Central
Google Scholar
Wu Z, McGoogan JM. Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239–42.
Article
CAS
PubMed
Google Scholar
WHO. Novel Coronavirus (2019-nCoV) situation report-22. 2020.
Jung JY, Yoon D, Choi Y, Kim HA, Suh CH. Associated clinical factors for serious infections in patients with systemic lupus erythematosus. Sci Rep. 2019;9(1):9704.
Article
PubMed
PubMed Central
CAS
Google Scholar
Ocampo-Piraquive V, Nieto-Aristizabal I, Canas CA, Tobon GJ. Mortality in systemic lupus erythematosus: causes, predictors and interventions. Expert Rev Clin Immunol. 2018;14(12):1043–53.
Article
CAS
PubMed
Google Scholar
Jorge A, Wallace ZS, Zhang Y, Lu N, Costenbader KH, Choi HK. All-cause and cause-specific mortality trends of end-stage renal disease due to lupus nephritis from 1995 to 2014. Arthritis Rheumatol. 2019;71(3):403–10.
Article
PubMed
PubMed Central
Google Scholar
Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, et al. Coronavirus infections and immune responses. J Med Virol. 2020;92(4):424–32.
Article
CAS
PubMed
PubMed Central
Google Scholar
Wan S, Yi Q, Fan S, Lv J, Zhang X, Guo L, et al. Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19) infected patients. Br J Haematol. 2020;189(3):428–37.
Article
CAS
PubMed
PubMed Central
Google Scholar
Matucci-Cerinic M, Bruni C, Allanore Y, Clementi M, Dagna L, Damjanov NS, et al. Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management. Ann Rheum Dis. 2020;79(6):724–6.
Article
CAS
PubMed
Google Scholar
Orlandi M, Lepri G, Bruni C, Wang Y, Bartoloni A, Zammarchi L, et al. The systemic sclerosis patient in the COVID-19 era: the challenging crossroad between immunosuppression, differential diagnosis and long-term psychological distress. Clin Rheumatol. 2020;39(7):2043–7.
Article
PubMed
PubMed Central
Google Scholar
Minniti A, Maglione W, Pignataro F, Cappadona C, Caporali R, Del Papa N. Taking care of systemic sclerosis patients during COVID-19 pandemic: rethink the clinical activity. Clin Rheumatol. 2020;39(7):2063–5.
Article
PubMed
PubMed Central
Google Scholar
Lechien JR, Chiesa-Estomba CM, De Siati DR, Horoi M, Le Bon SD, Rodriguez A, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol. 2020;277(8):2251–61.
Article
PubMed
PubMed Central
Google Scholar
Furer V, Rondaan C, Heijstek MW, Agmon-Levin N, van Assen S, Bijl M, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(1):39–52.
Article
CAS
PubMed
Google Scholar
Epidemiologists CoSaT. Interm-20-ID-01: standardized surveillance case definitions and national notification for 2019 novel coronavirus disease (COVID-19). 2020 2020.
Zhong J, Shen G, Yang H, Huang A, Chen X, Dong L, et al. COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study. Lancet Rheumatol. 2020;2(9):e557–64.
Article
PubMed
PubMed Central
Google Scholar
Aouhab Z, Hong H, Felicelli C, Tarplin S, Ostrowski RA. Outcomes of systemic lupus erythematosus in patients who discontinue hydroxychloroquine. ACR Open Rheumatol. 2019;1(9):593–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Peschken CA. Possible consequences of a shortage of hydroxychloroquine for patients with systemic lupus erythematosus amid the COVID-19 Pandemic. J Rheumatol. 2020;47(6):787–90.
Article
CAS
PubMed
Google Scholar
Jakhar D, Kaur I. Potential of chloroquine and hydroxychloroquine to treat COVID-19 causes fears of shortages among people with systemic lupus erythematosus. Nat Med. 2020;26(5):632.
Article
CAS
PubMed
Google Scholar
Michaud K, Wipfler K, Shaw Y, Simon TA, Cornish A, England BR, et al. Experiences of patients with rheumatic diseases in the United States during early days of the COVID-19 pandemic. ACR Open Rheumatol. 2020;2(6):335–43.
Article
PubMed
PubMed Central
Google Scholar
Gomides A. Impact of chronic use of antimalarials on SARS-CoV-2 infection in patients with immune-mediated rheumatic diseases: protocol design for a multicentric observational cohort in Brazil. JMIR Res Protoc. 2020;9:e23532.
Article
PubMed
PubMed Central
Google Scholar